Skip to main content

Table 1 Baseline cohort characteristics

From: Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Characteristic DUAL IIc cohort (patients receiving IDegLira)
Demographics and risk factors, mean (SD)
 Start age (years) 56.8 (8.9)
 Duration of diabetes (years) 10.3 (6.0)
 Percentage male (%) 56.3
 HbA1c (%) 8.7 (0.7)
 SBP (mmHg) 132.4 (14.8)
 Total cholesterol (mg/dL) 182.0 (45.5)
 HDL cholesterol (mg/dL) 43.4 (11.0)
 LDL cholesterol (mg/dL) 101.9 (37.1)
 Triglycerides (mg/dL) 196.8 (148.0)
 BMI (kg/m2) 33.6 (5.7)
 Percentage smokers (%) 16.1
 Cigarettes per daya 12.7
 Alcohol consumption (fl oz/week)b 4.66
Ethnic group, %
 White 70.9
 Black 4.5
 Hispanic 8.0
 Native American 0
 Asian/Pacific Islander 16.6
  1. BMI body mass index, HbA 1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic blood pressure
  2. aFrom [16]
  3. bFrom [17]
  4. cDUAL II is a randomized, controlled, double-blind, multinational, treat-to-target trial in which IDegLira was compared with IDeg over 26 weeks of treatment in patients with T2DM uncontrolled on basal insulin [7]